Friday, April 6, 2012

Compugen zeroes in on computational biology, cancer drugs

Compugen Inc. is betting that its algorithms — and the hiring of two Bay Area antibody drug veterans — add up to new treatments for cancer and other diseases that send the body’s immune system awry.
The South San Francisco-based U.S. subsidiary of the Israeli company Compugen Ltd. hired Mary Haak-Frendscho, formerly president and CEO of Takeda San Francisco, as executive chairman. John Hunter, most recently in charge of preclinical monoclonal antibody research at Berkeley’s Xoma Corp., was hired as site head and vice president of antibody R&D.
In all, Compugen will have a staff of 10 by the end of the year, Haak-Frendscho said, but will hire quickly.

No comments:

Post a Comment